Non-Melanoma Skin Cancer - Global Strategic Business Report

Report
196 Pages
September 2024
Region: Global
Global Industry Analysts, Inc
ID: 5309815

The global market for Non-Melanoma Skin Cancer is estimated at US$681.7 Million in 2023 and is projected to reach US$921.3 Million by 2030, growing at a CAGR of 4.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Basal Cell Carcinoma (BCC) Indication segment, which is expected to reach US$750.6 Million by 2030 with a CAGR of 4.7%. The Other Indications segment is also set to grow at 3.2% CAGR over the next 7 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $205.6 Million in 2023, and China, forecasted to grow at an impressive 4.1% CAGR to reach $161.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Non-Melanoma Skin Cancer Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Melanoma Skin Cancer Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Non-Melanoma Skin Cancer Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Accuray, Inc., Almirall S.A., Boehringer Ingelheim GmbH, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

Accuray, Inc.
Almirall S.A.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Elekta AB
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
iCAD, Inc.
Ion Beam Applications SA
Merck & Co., Inc.
Mylan NV
Novartis AG
Sensus Healthcare
Sun Pharmaceutical Industries Ltd.
Varian Medical Systems, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Non-melanoma Skin Cancer - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Non-Melanoma Skin Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Basal Cell Carcinoma (BCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 17: USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 18: USA Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 19: USA 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 20: USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 21: USA Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 22: USA 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

CANADA

Table 23: Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 24: Canada Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 25: Canada 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 26: Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 27: Canada Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 28: Canada 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

JAPAN

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 29: Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 30: Japan Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 31: Japan 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 32: Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 33: Japan Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 34: Japan 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

CHINA

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 35: China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 36: China Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 37: China 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 38: China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 39: China Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 40: China 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

EUROPE

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 41: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 42: Europe Historic Review for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 43: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 44: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 45: Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 46: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 47: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 48: Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 49: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

FRANCE

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 50: France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 51: France Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 52: France 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 53: France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 54: France Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 55: France 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

GERMANY

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 56: Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 57: Germany Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 58: Germany 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 59: Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 60: Germany Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 61: Germany 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

ITALY

Table 62: Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 63: Italy Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 64: Italy 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 65: Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 66: Italy Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 67: Italy 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

UNITED KINGDOM

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 68: UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 69: UK Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 70: UK 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 71: UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 72: UK Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 73: UK 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 74: Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 75: Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 76: Rest of Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 77: Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 78: Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 79: Rest of Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 80: Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 81: Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 82: Asia-Pacific 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 84: Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 85: Asia-Pacific 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

REST OF WORLD

Table 86: Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 87: Rest of World Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 88: Rest of World 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2024 & 2030
Table 89: Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
Table 90: Rest of World Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
Table 91: Rest of World 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Accuray, Inc.
Almirall S.A.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Elekta AB
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
iCAD, Inc.
Ion Beam Applications SA
Merck & Co., Inc.
Mylan NV
Novartis AG
Sensus Healthcare
Sun Pharmaceutical Industries Ltd.
Varian Medical Systems, Inc.

Table Information

Report Attribute	Details
No. of Pages	196
Published	September 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 681.7 Million
Forecasted Market Value ( USD ) by 2030	$ 921.3 Million
Compound Annual Growth Rate	4.4%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4622EUR$4,950USD£3,904GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€8782EUR$9,405USD£7,418GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€13866EUR$14,850USD£11,712GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 46 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Non-Melanoma Skin Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032

Global Skin Cancer Diagnostics and Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Merkel Cell Carcinoma Disease Treatment Market - Forecasts from 2024 to 2029

Global Skin Cancer Treatment Market Analysis & Forecast 2024-2034: Market By Indication; By Therapy; By Distribution Channel; and By Region

About the Non Melanoma Skin Cancer Drug Market